Document:

Document

Exhibit 10.5
			
	Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

SUPPLEMENTAL AGREEMENT NO. 19

to

Purchase Agreement No. 03735

between
    
THE BOEING COMPANY

and

AMERICAN AIRLINES, INC.

Relating to Boeing Model 737 MAX Aircraft 
This SUPPLEMENTAL AGREEMENT No. 19 (SA-19), entered into as of April _8__, 2021 (Effective Date), by and between THE BOEING COMPANY, a Delaware corporation with offices in Seattle, Washington (Boeing) and AMERICAN AIRLINES, INC. a Delaware corporation with offices in Fort Worth, Texas, together with its successors and permitted assigns (Customer);
WHEREAS, Boeing and Customer entered into Purchase Agreement No. 03735 dated February 1, 2013 relating to Boeing Model 737 MAX Aircraft, as amended and supplemented (Purchase Agreement) and capitalized terms used herein without definitions shall have the meanings specified therefore in such Purchase Agreement; 

    WHEREAS, Boeing and Customer have entered into Letter No. AAL-LA-2002714, entitled [****] and Letter Agreement No. AAL-PA-03735-LA-2002743 entitled [****], which both [****] the [****] for the following [****] ([****]) as June 2021:

						
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]

PA 03735    SA-19, Page 1
BOEING PROPRIETARY

[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

						
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]

    WHEREAS, Boeing and Customer agree that pursuant to Section 1.2 of the [****], Customer agreed to [****] to, [****], [****] the [****] and the [****] (each as defined in Section 1.2 of the [****]);   

     WHEREAS, in accordance with Section 1.2 of the [****], Customer has [****] to Boeing the [****] by [****], and the [****] for the [****];
 
WHEREAS, Customer has [****] to Boeing the [****] in a [****] to Boeing [****] for [****]; 

NOW, THEREFORE, the parties agree that the Purchase Agreement is amended as set forth below and otherwise agree as follows:

1.[****].

Customer and Boeing agree to [****] of [****] from [****] to [****] as shown in the table below, pursuant to the terms and conditions in the [****]. 

						
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]
	[****]	[****]

2.Table of Contents. 
The “Table Of Contents” to the Purchase Agreement referencing SA-18 in the footer is deleted in its entirety and is replaced with the new “Table Of 
PA 03735    SA-19, Page 2
BOEING PROPRIETARY

[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

Contents” (attached hereto) referencing SA-19 in the footer to reflect changes made to the Purchase Agreement by this SA-19.  Such new Table of Contents is hereby incorporated into the Purchase Agreement in replacement of its predecessor.
3.Tables.
3.1    Table 1R11.   Table 1R11, entitled “Base Weight 737-8 Aircraft Delivery, Description, Price, and Advance Payments” referencing SA-18 in the footer  is deleted in its entirety and replaced with Table 1R12, entitled “737-8 Aircraft Delivery, Description, Price, and Advance Payments” (attached hereto) referencing SA-19 in the footer (Table 1R12).   Table 1R12 is hereby incorporated into the Purchase Agreement in replacement of Table 1R11.  [****].
3.2    Table 1-3R5.   Table 1-3R5 entitled “[****] Aircraft Delivery, Description, Price, and Advance Payments” referencing SA-18 in the footer is deleted in its entirety and replaced with Table 1-3R6, entitled “[****] Aircraft Delivery, Description, Price, and Advance Payments” (attached hereto) referencing SA-19 in the footer (Table 1-3R6). Table 1-3R6 is hereby incorporated into the Purchase Agreement in replacement of Table 1-3R5. [****].

4.Miscellaneous.
4.1    The Purchase Agreement is amended as set forth above by the revised Table of Contents, Table 1R12, and Table 1-3R6.  All other terms and conditions of the Purchase Agreement remain unchanged and are in full force and effect.
4.2    References in the Purchase Agreement and any supplemental agreements and associated letter agreements to “Table 1” or “Table 1R2” or “Table 1R3”, or “Table1R4 and Table 1-2” or “Table 1(R4) and Table 1-2”, “Table 1R5 and Table 1-2”, “Table 1R6, Table 1-2, and Table 1-3”,  “Table 1R7, Table 1-2, and Table 1-3R1”,“Table 1R8, Table 1-2, and Table 1-3R2”, “Table 1R9, Table 1-2, and Table 1-3R3”, “Table 1R10, Table 1-2, and Table 1-3R4”, “Table 1R11, Table 1-2, and Table 1-3R5” are deemed to refer to “Table 1R12, Table 1-2, and Table 1-3R6”.  
References in the Purchase Agreement and any supplemental agreements and associated letter agreements to “Table 1R4” or “Table 1R5” (where no corresponding reference to Table 1-2 is made) are deemed to refer to “Table 1R12 and Table 1-3R6”, (including without limitation, and for the avoidance of doubt, the references to Table 1R4 in Section 3 of Supplemental Agreement No. 9 dated April 6, 2018). However, references to Table 1R5 in Letter Agreement AAL-PA-LA-1106650R4 entitled “[****]” is deemed to only refer to Table 1R12 and the references to Table 1R5 in the Slide Letter Agreement remain references to Table 1R5.
PA 03735    SA-19, Page 3
BOEING PROPRIETARY

[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

References in the Purchase Agreement and any supplemental agreements and associated letter agreements to “Table 1R6”, “Table 1R7”, “Table 1R8”, “Table 1R9”, “Table 1R10” or “Table 1R11” (where no corresponding reference to either Table 1-2 or Table 1-3 is made) are deemed to refer to only “Table 1R12”.
Additionally, for the avoidance of doubt, references in the Purchase Agreement and any supplemental agreements and associated letter agreements to “Table 1-2” (where no corresponding reference to Table 1R4 or Table 1R5 is made) remain references to “Table 1-2”.
4.3 On or before [****], Boeing will, pursuant to Section 6.1 of the [****] Agreement (and by [****] concurrent with the execution of this SA-19), [****] to Customer the [****] in the [****] of [****] ([****]) as shown in the table below.

												
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
	[****]	[****]	[****]	[****]
			[****]	[****]

Intentionally Left Blank
PA 03735    SA-19, Page 4
BOEING PROPRIETARY

[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

									
	AGREED AND ACCEPTED this		
			
	April 8, 2021		
	Date		
			
	THE BOEING COMPANY		AMERICAN AIRLINES, INC.
			
	/s/ The Boeing Company		/s/ American Airlines, Inc.
	Signature		Signature
			
	The Boeing Company		American Airlines, Inc.
	Printed name		Printed name
			
	Attorney-in-Fact		VP, Treasurer
	Title		Title

PA 03735    SA-19, Page 5
BOEING PROPRIETARY

[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

TABLE OF CONTENTS 
									
	ARTICLES	SA
NUMBER

	Article 1.
	Quantity, Model and Description	
	Article 2.
	Delivery Schedule	
	Article 3.
	Price	
	Article 4.
	Payment	
	Article 5.
	Additional Terms	
	Article 6.
	Confidentiality	
	TABLE	
	1R12
1-2
1-3R6
	Aircraft Information Table
Revised Delivery Aircraft Information Table
[****] Aircraft Delivery, Description, Price, and Advance Payments
	19
9
19

	EXHIBITS	
	AR1
A2
	Aircraft Configuration
Revised Delivery Aircraft Configuration
	6
9

	B.
	Aircraft Delivery Requirements and Responsibilities	
	C.
	Definitions	
	SUPPLEMENTAL EXHIBITS	
	AE1.
	[****]	
	BFE1.
	BFE Variables	
	CS1R1.
	Customer Support Variables	4
	EE1.
	[****]	
	SLP1.
	[****]	
	LETTER AGREEMENTS	
	LA-1106648R1	Special Matters	6
	LA-1106649	[****]	
	LA-1106650R4	[****]	11
	LA-1106651R2	[****]	11

PA-03735                            TABLE OF CONTENTS, Page 1 of 3                            SA-19
BOEING PROPRIETARY
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

									
			
	LA-1106652	Aircraft Model Substitution	
	LA-1106654	AGTA Terms Revisions for MAX	
	LA-1106655	Open Matters – 737 MAX  Withdrawn
	6
	LA-1106656R1	[****]	1
	LA-1106657R1	[****]	2
	LA-1106663 R1	[****]	2
	LA-1106664 R1	[****]	2
	LA-1106658	[****]	
	LA-1106659R2	[****]	10
	LA-1106660	Spare Parts Initial Provisioning	
			
	LETTER AGREEMENTS, continued	SA
NUMBER

	LA-1106661R2	[****]	2
	LA-1106667	[****]	
	LA-1106668R1	[****]	8
	LA-1106669	[****]	
	LA-1106670	Confidentiality	
	LA-1106671R1	Miscellaneous Commitments	1
	LA-1106672	Extended Warranty Option	
	LA-1106673R1*	[****]	4
	LA-1106677	Optional Features Comfort Letter	
	LA-1600073	[****]	4

LA-1600852              [****]                                                    5
LA-1603773            [****]                                                                 5
LA-1605402            [****]                                                    6
LA-1700919              [****]                                              7
LA-1801206              [****]                                                           9
LA-2002704           [****]                                                  11
PA-03735                            TABLE OF CONTENTS, Page 2 of 3                            SA-19
BOEING PROPRIETARY
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

LA-2002743           [****]                                           11
LA-2003342              [****]                                           11
LA-2003486             [****]                                           14

* -   This is an intended gap as there are no Letter Agreements LA-1106674 through LA-1106676 incorporated by the Purchase Agreement.

PA-03735                            TABLE OF CONTENTS, Page 3 of 3                            SA-19
BOEING PROPRIETARY
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]

Table 1R12 To
Purchase Agreement No. PA-03735
737-8 Aircraft Delivery, Description, Price and Advance Payments

																								
	Airframe Model/MTOW:	737-8	[****] pounds		Detail Specification:		[****]	
	Engine Model/Thrust:	CFMLEAP-1B25	[****] pounds		Airframe Price Base Year/Escalation Formula:	[****]		[****]
	Airframe Price:		$[****]		Engine Price Base Year/Escalation Formula:			
	Optional Features:		$[****]					
	Sub-Total of Airframe and Features:		$[****]		Airframe Escalation Data:
			
	Engine Price (Per Aircraft):		$[****]		Base Year Index (ECI):		[****]	
	Aircraft Basic Price (Excluding BFE/SPE):		$[****]		Base Year Index (CPI):		[****]	
	Buyer Furnished Equipment (BFE) Estimate:		$[****]					
	Seller Purchased Equipment (SPE) Estimate:		$[****]					
	LIFT Seats Provided by Boeing (Estimate):		$[****]					
	Deposit per Aircraft:		$[****]					

																														
	DeliveryDate
	Numberof
Aircraft
	EscalationFactor
(Airframe)
	ManufacturerSerial Number
	NominalDelivery
Month
	EscalationEstimate
Adv Payment Base
Price Per A/P
	Advance Payment Per Aircraft (Amts. Due/Mos. Prior to Delivery):
	At Signing
[****]
	[****]
[****]
	[****]
[****]
	Total
[****]

	[****]-2017	1	[****]	44459	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2017	1	[****]	44463	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2017	1	[****]	44465	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2017	1	[****]	44446	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44447	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44451	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44448	N/A	$[****]	$[****]	$[****]	$[****]	$[****]

AAL=PA-03735 108567-1F.txt    Boeing Proprietary        SA-19
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]    Page 1

																														
	[****]-2018	1	[****]	44449	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44455	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44450	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44452	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44453	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44454	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44456	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44457	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44458	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44460	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44461	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44462	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2018	1	[****]	44464	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44466	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44467	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44468	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44469	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44471	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44470	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44472	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44473	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44474	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44476	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44475	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44477	N/A	$[****]	$[****]	$[****]	$[****]	$[****]

AAL=PA-03735 108567-1F.txt    Boeing Proprietary        SA-19
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]    Page 2

																														
	[****]-2019	1	[****]	44479	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44478	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44481	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44480	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44482	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44483	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44484	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2019	1	[****]	44485	N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2020	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2020	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]

Total    42

AAL=PA-03735 108567-1F.txt    Boeing Proprietary        SA-19
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]    Page 3

Table 1-3R6 To
Purchase Agreement No. PA-03735
[****] Aircraft Delivery, Description, Price and Advance Payments

																								
	Airframe Model/MTOW:	737-8	[****] pounds		Detail Specification:		[****]	
	Engine Model/Thrust:	CFMLEAP-1B25	[****] pounds		Airframe Price Base Year/Escalation Formula:	[****]		[****]
	Airframe Price:		$[****]		Engine Price Base Year/Escalation Formula:			
	Optional Features:		$[****]					
	Sub-Total of Airframe and Features:		$[****]		Airframe Escalation Data:
			
	Engine Price (Per Aircraft):		$[****]		Base Year Index (ECI):		[****]	
	Aircraft Basic Price (Excluding BFE/SPE):		$[****]		Base Year Index (CPI):		[****]	
	Buyer Furnished Equipment (BFE) Estimate:		$[****]					
	Seller Purchased Equipment (SPE) Estimate:		$[****]					
	LIFT Seats Provided by Boeing (Estimate):		$[****]					
	Deposit per Aircraft:		$[****]					

																														
	DeliveryDate
	Numberof
Aircraft
	EscalationFactor
(Airframe)
	ManufacturerSerial Number
	NominalDelivery
Month
	EscalationEstimate
Adv Payment Base
Price Per A/P
	Advance Payment Per Aircraft (Amts. Due/Mos. Prior to Delivery):
	At Signing
[****]
	[****]
[****]
	[****]
[****]
	Total
[****]

	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]

AAL-PA-03735 108567-1F.txt    Boeing Proprietary        SA-19
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]    Page 1

Table 1-3R6 To
Purchase Agreement No. PA-03735
[****] Aircraft Delivery, Description, Price and Advance Payments

																														
	DeliveryDate
	Numberof
Aircraft
	EscalationFactor
(Airframe)
	ManufacturerSerial Number
	NominalDelivery
Month
	EscalationEstimate
Adv Payment Base
Price Per A/P
	Advance Payment Per Aircraft (Amts. Due/Mos. Prior to Delivery):
	At Signing
[****]
	[****]
[****]
	[****]
[****]
	Total
[****]

	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2023	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]
	[****]-2024	1	[****]		N/A	$[****]	$[****]	$[****]	$[****]	$[****]

Total    18

AAL-PA-03735 108567-1F.txt    Boeing Proprietary        SA-19
[****]=[CONFIDENTIAL PORTION HAS BEEN OMITTED BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED]    Page 2skye_ex101.htm

EXHIBIT 10.1
  
 SKYE BIOSCIENCE, INC.
  
 July 21, 2021
  
 Holder of Common Stock Purchase Warrants
  
 Re:       Inducement Offer to Exercise Common Stock Purchase Warrants
  
 Dear Holder:
  
 Skye Bioscience, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued to you on August 4, 2020 (the “Existing Warrants”), as set forth on the signature page hereto and currently held by you (the “Holder”). The issuance of the shares of Common Stock underlying the Existing Warrants (the “Warrant Shares”) has been registered pursuant to the registration statements on Form S-1 (File Registration Nos. 333-239826 and 333-240226) (collectively, the “Registration Statement”). The Registration Statement is currently effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants.
  
 In consideration for exercising in full all of the Existing Warrants held by you and set forth on the Holder's signature page hereto (the “Warrant Exercise”) at the exercise price per Warrant Share as set forth in the Existing Warrants of $0.06 per share, the Company hereby offers to issue you or your designee:
  
 a new unregistered Common Stock Purchase Warrant (“New Warrant”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”), to purchase up to a number of shares (the “New Warrant Shares”) of Common Stock equal to 100% of the number of Warrant Shares issued pursuant to the Warrant Exercise hereunder, which New Warrant shall be substantially in the form as reflected in Exhibit A hereto, will be exercisable immediately, and have a term of exercise of five (5) years, and an exercise price per share equal to $0.15.
  
 The original New Warrant certificate(s) will be delivered within three (3) Trading Days following the date hereof. Notwithstanding anything herein to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (“Beneficial Ownership Limitation”) set forth in Section 2(e) of the Existing Warrants (or, if applicable and at the Holder’s election, 9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing Warrant (provided no additional exercise price shall be due and payable).
  
 Expressly subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below, with such acceptance constituting Holder's exercise in full of the Existing Warrants for an aggregate exercise price set forth on the Holder’s signature page hereto (the “Warrants Exercise Price”) on or before 11:00 p.m., Eastern Time, on July 21, 2021 (the “Execution Time”).
  
 	 
	
	

	 

  
 Additionally, the Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto. Holder represents and warrants to the Company that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an “accredited investor” as defined in Rule 501 of the Securities Act, and agrees that the New Warrants will contain restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered under the Securities Act, except as provided in Annex A attached hereto. Also, Holder represents and warrants to the Company that (i) it is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of the New Warrants (this representation is not limiting Holder’s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise in compliance with applicable federal and state securities laws), and (ii) the Holder understands that an investment in the Company involves a high degree of risk including risks set forth in the SEC Reports, and the Holder has had an opportunity to review the SEC Reports.
  
 The Holder understands that the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the following:
  
 “THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.” 
  
 Certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above), (i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act unless such sale is to a person deemed to control the Company, (iii) if such New Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the New Warrant), without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv) if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrant) and the Company is then in compliance with the current public information required under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, or (v) if such legend is not required under applicable rules and regulations of the Securities Act (including judicial interpretations and pronouncements formally issued by the staff of the Securities and Exchange Commission (the “Commission”) and the earliest of clauses (i) through (v), the “Delegend Date”)). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued free of all legends. The Company agrees that following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than two (2) Trading Days following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued with a restrictive legend (such second (2nd) Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request of the Holder shall credit the account of the Holder’s prime broker with the Depository Trust Company System as directed by the Holder. 
  
 	 
	
	

	 

  
 In addition to the Holder’s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate representing the New Warrant Shares so delivered to the Company by the Holder that is free from all restrictive and other legends and (b) if after the Legend Removal Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B) the lowest closing sale price of the shares of Common Stock on any Trading Day during the period commencing on the date of the delivery by the Holder to the Company of the applicable Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this clause (B). 
  
 From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (A) except for Exempt Issuances (as defined hereunder), issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file any registration statement or any amendment or supplement to any existing registration statement (other than a resale registration statement referred to herein, prospectus supplements to the Registration Statements to reflect the transactions contemplated hereby which the Company may file in its discretion, and/or a universal “shelf” registration statement on Form S-3). 
  
 “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any securities issued hereunder or issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement, (c) any securities issuable to the Placement Agent or its designees in connection herewith or any securities issuable upon conversion or exercise or exchange of any such securities or (d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the thirty day prohibition period included herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.
  
 	 
	
	

	 

  
 If this offer is accepted and the transaction documents are executed by the Execution Time, then on or before 8:00 a.m., Eastern Time, on July 22, 2021, the Company shall issue a press release and/or file a Current Report on Form 8-K with the Commission disclosing all material terms of the transactions contemplated hereunder. From and after the issuance of such press release or the filing of such Current Report on Form 8-K, as applicable, the Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the issuance of such press release and/or Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of this offer, the Warrant Shares shall be issued free of any legends or restrictions on resale by the Holder.
  
 No later than the second (2nd) Trading Day following the date hereof, the closing shall occur at such location as the parties shall mutually agree. Unless otherwise directed by H.C. Wainwright & Co., LLC (the “Placement Agent”), settlement of the Warrant Shares shall occur via “Delivery Versus Payment” (“DVP”) (i.e., on the Closing Date, the Company shall issue the Warrant Shares registered in the Holders’ names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the applicable Holder, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). The date of the closing of the exercise of the Existing Warrants shall be referred to as the “Closing Date”.
  
 The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement.
  
 ***************
  
 	 
	
	

	 

  
 	 	 Sincerely yours,
  
 SKYE BIOSCIENCE, INC.
	
	 	 	 	 
		By:		
	  
	 Name: 
		 
	 	Title:  		 

  
 	 
	
	

	 

  
 Accepted and Agreed to:
  
 Name of Holder: ________________________________________________________
  
 Signature of Authorized Signatory of Holder: _________________________________
  
 Name of Authorized Signatory: _______________________________________________
  
 Title of Authorized Signatory: ________________________________________________
  
 Number of Existing Warrants: __________________
  
 Aggregate Warrant Exercise Price: _________________
  
 New Warrants: (100% of total Existing Warrants being exercised): ___________
  
 Beneficial Ownership Blocker: ☐ 4.99% or ☐ 9.99%
  
 DTC Instructions:
  
 	 
	
	

	 

  
 Annex A
  
 Representations, Warranties and Covenants of the Company. The Company hereby makes the following representations and warranties to the Holder:
  
 	 a)
	 SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein “SEC Reports”). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. To the best knowledge of the Company, the Company has never been an issuer subject to Rule 144(i) under the Securities Act.

	  
	  

	 b)
	 Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

	  
	  

	 c)
	 No Conflicts. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.

	  
	  

	 d)
	 Registration Obligations. As soon as practicable (and in any event within 90 calendar days of the date of this letter agreement), the Company shall prepare and file with the Commission a registration statement relating to the resale of the New Warrant Shares by the holders of the New Warrants under the Securities Act and use commercially reasonable best efforts to cause such registration statement to be declared effective by the Commission as soon as practical thereafter.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00331-of-00352.parquet"}]]